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The long-term outcome of 217 consecutive survivors of cardiac
arrest whose therapy was guided by at irephyaiulugiclustingwas
analyzed. After eleclrophysiolopir testing, St patients (37%) were
classified as having no Inducible arrhythmia and were treated
without aatierrhythmic drugs; 23 received an implantable de .
llhrillator. Of the 136 patients with inducible arrhythmia, the 51
(38%) who responded to serial drug testing were treated with the
saecessful drug and the 35 (62%) with unssovessful drug testing
were treated with an hnptantable defibrillator (47 patients),
amiodaroue (36 patients) or drops that were unsuccessful during
testing (2 patients) . The mean fallow-up interval For all patients
was 35 ± 23 mouths.
The actuarial Incidence of sudden death and overall death was
similar for patients whose arehytlmias were not inducible, drag
responders and nonresponders. The actuarial incidence rate of
recurrent arrhythmic events In nonresponders was 35 ± 5% and
53 ± 7% at 2 and 5 years, respectively . These values were
signlhcaully lower (and statistically similar to each other) to the
other two patient groups : patients with nnnindueihle arrhythmia
Although electeophysierlogic sealing is often considered a
necessary step in determining therapy for survivors of car
.
diac arrest, there are few actuarial data on the outcome of
therapy guided by such testing in these patients . Conse-
quently . the long-term prognosis is not well characterized for
some subsets of these patients whose therapy is based on
eltorophysiologic testing
. The present retrospective analy-
sis attempts to estimate the lung-term
efficacy
of therapy
guided by clectrophysiologic testing in a large group of
survivors of cardiac arrest-
Methods
Study patients (Table Ii
. The study group consisted of
217 consecutive survivors of cardiac arrest referred to our
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(19 ± 5S, and 31 ± 7%, respectively, p c 0.05) and drug
responders (13 t 5% and 23 t 5%, eospa tivdy, p a 0.01) .
t'alients with an implantable defibrillator who had recurrent
arrhythmic events were sianlgcandy less likely to the suddunly
than were patients without a defibrillator who had recurrent
events (p < 0.001).
The eteclrophystelsgic study was useful in subgrouping survi-
vurs of cardiac aresstinm rnl 5ively high risk (nourespordoes) and
low risk (patients with no inducible arrhythmins and drug re-
sponders) groups, but even the low risk groups had a substantial
cumulative risk of recurrent arrhythmic events, With an implant .
able degbrlgator, mortality in the high risk group was similar to
that in the low risk groups despite a significantly higher incidence
of recurrent mAythmic events- The use of the implanlahle
defibrillator should be studied prospectively in survivors of car-
diac arrest who respond to drug testing or have no Inducible
arrhythmia .
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center between July L982 and January 1990 whose therapy
subsequently was guided by invasive electeophysiologic
testing . Each patient had presented with sustained ventric-
ular taehyeardia or ventricular fibrillation that occurred in
the absence of acute myocardial infarction and caused a loss
of consciousness that required cardiopulmonary resuscita-
lion. The clinical characteristics of these patients are shown
in Table I .
Elecfropkysiofogfc Testing
The stimulation protocols used in electrophysiologie test-
ing and the definitions used for arrhythmia inducibility and
noninducibility and drug response remained the same
throughout this series . Before baseline (drug-free) electro
.
physiologic testing, all 217 patients went through a period of
stabilization in which all class I antiarrhythmic medications
were withdrawn, metabolic disturbances were corrected and
therapy for isehem is heart disease (including coronary artery
bypass grafting, if necessary) and congestive heart failure
was optimized . All but 7 of the 217 patients underwent their
initial electrophysiologic study in the drug-free state ; these 7
0735-1097192155.00
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1 . Clinical Characteristics of 217 Pelicans
Patient Group
Ali
were taking amiodarone because they had required it before
testing to stabilize frequent recurrent ventricular arrhyth-
mia.
Baseline eleetrophysiologic testing . This was performed
initially with the pacing lead positioned in the right ventric-
ular apex. After eight paced heats at each of three cycle
lengths (600, 500 and 400 ms) . first single, then double, then
triple extrastimuli were added and each coupling interval
was progressively reduced to ventricular refractoriness or to
200 ms. Burst pacing was then performed with 8 to 12 beats
at cycle lengths from 350 ms to ventricular refractoriness or
to 200 ms. If a ventricular tachyarrhythmia was not induced .
the entire protocol was repeated front the right ventricular
outflow tract
. If a ventricular tachyarrhythmia was still not
induced, an isopruturenol infusion of u5 yng/miu was begun
(unless clinically contraindicated) to increase
the
rest heart
rate to 110 to 130 beatsimin and stimulation was repeated
.
Inducibility war defined as the ability to reproducibly
induce at least 10 beats of a ventricular tachyarrhythmia of
any configuration . In general . the entire protocol was com-
pleted unless sustained ventricular tachycardia was induced .
However, if several episodes of symptomatic. hemudynam-
ieally compromising nonsustained ventricular tachycardia
(that is, terminating spontaneously after 10 beats and before
30 s) were reproducibly induced. the baseline protocol was
occasionally not carried to completion
. Of the 217 patients
.
136 (63%) were categorized as having inducible arrhythmia
during the initial study (including all 7 who were receiving
amiodarone) and the remaining 81 were considered to have
no inducible arrhythmia . The mean cycle length of the
initially induced arrhythmia was 235 ± 59 ms.
Serial drug testing. For patients who had inducible ven-
tricular tachyarrhythmia, serial drug testing was performed
with the same stimulation protocol used during the baseline
study. We tested the following drugs unless they had been
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< 0
.05. patients with noninducible armymmla versus drug
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unsuccessful or had caused toxicity during empiric trials or
were clinically contraindicated : procainamide, quinidine,
phenytoin . disopyramide and mexiletine (usually in combi-
nation with a class la agent) . In patients whose clinical
arrhythmia was associated with exercise or in whom an
isoprolerenol infusion was required to induce the arrhyth-
mia, we also tested beta-adrenergic blocking agents or
verapamil . or both
. We did not test class Ic agents in these
survivors of cardiac arrest .
A patient was
considered a drug responder if no more
than nine beats of ventricular tachycardia were seen during
an electrophysiologlc drug study and if the patient was
subsequently discharged on treatment with adequate doses
of that drug . The 136 patients with inducible arrhythmias had
a mean of 2.8 ± 1 .7 drug tests. Fifty-one (38%) of the 136
were drug responders (I8 responding to phenytoin, 13 to
quinidine, I I to procainamide, 3 to a combination of mexi-
letine plus a class la drug. 2 to timolol and I each to
mexiletine alone, disopyramide vesapatail and amiodarone
plus procainamide). The other 85 patients (62%p) with induc-
ible arrhythmia had unsuccessful serial drug testing and were
classified as nonresponders. The clinical characteristics of
all 217 patients in the total study group, are shown in
Tahle I .
Therapy
Patients without Inducible arrhythmim
. For these g1 pa-
tients the primary therapy was withholding of all class I and
class Ill antiarrhythmic dregs . In addition, an attempt was
made in each case to locate a reversible cause for the index
arrhythmia and to advise the patient and the referring
physician to take preventive measures
. Finally, beginning in
1988, because of new reports (1,2) suggesting that survivors
of cardiac arrest with noninducible arrhythmia might not
Tow ..
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have a benign prognosis, such patients in this series whG did
net have an identifiable reversible cause for the index
arrhythmia were offered treatment with an implantable de-
fibrillator- Antiarrhythmic medications were withheld in the
patients in this group who received the device,
Drug responders. For these 51 patients, therapy was
based on long-term use of the drug that was successful
during etectrephysiologic study. Target drug levels far tong-
terra thcrEpy were defined as the drug levels measured
during the successful electrophysiolagic study .
Nonresponders. For these 85 patients the therapy of
choice was the implantable defibrillator. The device was
used in 47 nonrcspoedcrs ; in the other 39 it was refused by
the patient or was unavailable (the implantable defibrillator
was extremely difficult to obtain during some periods in 1985
and 198fi 131) or the patient's general medical condition was
such that survival after surgery or [or an extended period
after implantation was considered unlikely . Our assessment
of the patient's general medical condition was subjective and
was based largely on the patient's functional capacity and
the presence and severity of underlying cardiac, peripheral
vascular, cerebrovascular, renal, psychiatric and pulmonary
disease .
In the 38 nonresponders cviw
did rim receive an implant-
able defibrillator, therapy with amiodarone was recom-
mended . From 1982 to 1987 the use of this drug was entirely
empiric
. Beginning in 1987, electrophysiologic testing was
offered after I to 2 weeks of therapy with amicdarone . 1'
during the study of amiodarone the resulting arrhythmia
caused hemodynamic collapse, an attempt was made to add
a second drug that further slowed the induced anhythmia .
For nomesponders who also refused therapy with amie-
daone, an attempt was made to select the best ineffective
drug tested, that is, the drug that resulted in the slowest
induced arrhythmia or made the induced arrhythmia rela-
tively difficult to induce .
Follow-up . Patients who received the implantable
de-
fibrillator were seen in our center every 2 to 3 months . Other
patients were generally returned to their referring physicians
for follow-up care . Patients not actively followed up in our
center were contacted by telephone approximately every
year
. The current status of 213 of the 217 patients in this
study was ascertained between November 1990 and May
1991. Four patients in this study were lost to follow-up study
after 18, 25, 28 and 59 utonths of follow-up
. respectively .
Definitions. A recurrent arrhythmic event was defined as
I) recurrent sustained veetrirulartachycardin or ventricular
fibrillation that required intervention for ierminalion, 2) an
appropriate shock delivered by an implantable defibrillator,
or 3) sudden death . An appropriate shock was defined as
delivery of a shock or a series of shocks by an implantable
defibrillator in response to syncope, presyncope or severe
light-headedness.
Sudden death was defined as unexpected death that
occurred during sleep or within l h of the onset of symp
toms . Two patients who had sudden loss of consciousness
sudden c pal
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Figure L Actuatialincidence of sudden death (SO), overall death
(CID) and recanenl arrhythmic events (RE) in all 217 survivors of
cardiac arrest . The
table gives the number of patients (numerator)
and the percent standard coon {denominator) for each actuarial
curve at yearly intervals of follow-up .
due to ventricular tachyarrhyt h miss that required cardiopul-
monary resuscitation but that resulted in ultimately terminal
coma were tabulated as having sudden death
.
Statistical methods. Values are reported as mean values
SD . Actuarial analysis of longitudinal follow-up data was
calculated by the Kaptan-Meier method and actuarial values
are reported as mean values ± SE. Actuarial curves were
compared with use of the Mantel rank order test and mean
values with use of the Student r test. Proportions were
compared with the chi-square test. Statistical significance
was defined as a p value < 0.05 .
Results
The mean follow-up interval for all 217 patients was 35 t
23 months
. The actuarial incidence rates of recurrent ar-
rhythmic events, sudden death and overall mortality for all
217 patients are shown in Figure 1 .
Patients Without Inducible Arrhyrhmias
Of the 81 patients classified as having no inducible
arrhythmia after baseline testing, only 2 were inking a class
I or class Ill antiarrhylhmic agent duriugfollow-up
. Twenty-
three 128%) of the 81 patients received an implantable
defibrillator. The mean follow-up interval for all 81 patients
was 32 ± 21 months .
The arruarial risk of
recurrent arrhythmic events in this
group was 19 t
5% at 2 years and 31 ± 7% at 5 years (Fig .
2) . Twenty-five patients with no inducible arrhythmia died
during follow-up (Table 21. The overall actuarial mortality
rate was 22 ± 5% at 2 years and 37 a 7% at
5 years (Fig. 3) .
None of the 23 patients without irrdaci bte arrhythmia who
received the implantable defibrillator died suddenly . In the
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Figure 2. Actuarial incidence of recurrent arrhythmic events in 81
patients with noninducibte arrhythmia (N1) . 51 drug responders
(DR) and 85 nonrespunders (NR). The table gives the number of
patients (numerator) and the percent standard error (denominator)
for each actuarial curve at yearly intervals of follow-up .
58 patients who did not receive the device, 9 of 10 recurrent
arrhythmic events were manifested by sudden death . The
actuarial risk of sudden death for all 81 patients was 8
.
3%
at 2 years and 19 ± 7% at 5 years (Fig . 4). For patients
without the implantable defibrillator, this risk was 14 -_ 5%
at 2 years and 28 m 8% at 5 years
.
Influence of an identifiable reversible cause on outcome
. In
42 (52%) of the 81 patients with no inducible arrhythmia, a
possible reversible cause for the presenting arrhythmia was
identified. These included cardiac ischemia in 20 (cardiac
ischemia was identified as a potential reversible cause if
1) the clinical setting of the presenting arrhythmia was one in
which an increased myocardial oxygen demand was likely in
a patient with documented coronary artery disease, or
2) frank angina preceded the presenting arrhythmia), the use
of class I antiarrhythmic drugs in 15 . acute alcohol toxicity in
4 and hypoxemia due to exacerbation of chronic lung disease
in 3 . There was no significant difference between the 2-year
actuarial risk of recurrent arrhythmic events in the 42
patients with a reversible cause for presenting arrhythmia
(16 s 6%) and that in the 39 patients without an identifiable
reversible cause (22 ± 7%).
Table 2 . Mode of Death in 217 Patients
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Figure 3 . Actuarial incidence of overall death in 81 patients with
noninducibte arrhythmia (N), 51 drum responders (DR) and 85
nonresponders (NR) . The table gives the number of patients (nu-
merate) and the percent standard error (denominator) for each
actuarial curve at yearly intervals or fallow-up-
However, only I of the 20 patients in whom ischemia was
the presumed reversible cause for arrhythmias had a recur-
rent event. The actuarial risk of recurrent events in these 20
patients was 5 '-
5% at 2 years versus 24 t 9% in the 22
patients who had a reversible cause other than ischemia (p <
0. D.
Drag ,csponders
These 5
1 patients were followed up for a mean of 35 20
months . During this time drug intolerance developed in three
patients who underwent further electrophysiologic testing to
Figure 4. Actuarial incidence of sudden death in 81 patients with
noninducible arrhythmia INI), 51 drug responders (DR) and 85
nonresponders )NR(. The table gives the number of patients (nu-
merator) and the percent standard error (denominator) for each
actuarial curve at yearly intervals of follow-up .
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attempt to identify a second successful drug
.
In two of the
gable 3. Comparison of Overall Actuarial Outcomes in
three a second successful drug was found
; 7n the third an
implantable defibrillator was inserted .
The actuarial risk of recurrent arrhythmic events was 13
t 5% at 2 years and 23 ± 8% at 5 years (Fig . 2) . Seventeen
drug responders died during follow-up (Table 2) . The overall
actuarial mortality rate was 24 ± 69% at 2 years and
45
- 8%
A 5 years (Fig. 3).
Sudden death was the first manifestation of arrhythmia
recurrence in six of nine patients who had recurrent arrhyth-
mias . Among the three patients who survived the recur-
rences, two were subsequently treated with an implantable
defibrillator and one was treated empirically with aaao-
darone . The actuarial risk of sudden death For all 51 drug
responders was 6 3% at 2 years and ti ± 7% at 5 years
(Fig. 4).
Influence of specific drugs used. The risk of recurrent
arrhythmic events was not significantly related to the spe-
cific successful drug used . Recurrent events were seen in 3
of IS patients treated whit phenytoin, t of 13 treated with
quinidine, 4 of 11 treated with precainamide and I ai - 2
treated with rimolol.
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defibrillator (9 such deaths in 47 patients) (p ° 0,01). The
overall actuarial mortality rate in nonresponders who did not
receive an implantable defibrillator was 34 ± 8% at 2 years
and 61 r 9% at 5
years
.
Comparison of nutenmes for patients without inducible
arrhythmias, drug responders and
nonrsponders. Compari-
sons of the actuarial incidences of recurrent arrhythmic
events, sudden death and overall mortality among these
three groups
of
patients arc shown in Table 3
. The three
groups had almost identical actuarial sudden death mortality
and total mortality. Patients who had no inducible arrhyth-
mias at baseline and those whose arrhythmia was rendered
noninducihle during drug testing had statistically similar
incidence rates of recurrent arrhythmic events that were
significantly lower than rates for nonresponders
.
Influence of ejection fraction en recurrent arrhythmic
events (Table 4) . Patients without inducible arrhythmia and
nonresponders with a left ventricular ejection fraction x30%
had significantly more recurrent arrhythmic events during
follow-up than did patients with a higher ejection fraction .
The same trend was present for drug responders but did not
reach statistical significance . However, the range of ejection
fractions in patients who had recurrent arrhythmic events
was wide in all three groups.
Table 4
. Influence of Ejection Fraction on Recurrent
Arrhythmie Events
Nenrere
.sponders
The mean follow-up interval for these 85 patients was 38
25 months. Forty-seven (55%) of these patients received
an implantable defibrillator. Twenty-nine (62%) of the 47
also received antiarrhythmic drug therapy to reduce the
frequency of atria[ or ventricular aerhythmias (21 received
amiadanme and 8 received a class Ia or lb drug]. Of the 38
patients (45%) who did not receive an implantable defibril-
lator, 36 were treated with amiodarouc and 2 refused amia-
darone and were treated with a dnrg that had been ineffective
during serial drug testing .
The actuarial risk of recurrent arrhythmto eo'enrs in this
group was 35 ± 5% at 2 years and 53 ± i% at 5 years (rig .
2). Thirty-two nonresponders died during follow-up (Table
2). The overall actuarial mortality rare was 17 a 4% at 2
years and 46 t 7% at 5 years (Fig. 31 .
Sudden death. Ten nonresponders experienced sudden
death . For patients without the implantable defibrillator,
sudden death was the first manifestation of recurrent an
rhythmias in R of I I patients who had recurrent events . Two
patients with an implantable defibrillator died suddenly (in
one of these cases the defibrillator battery was depletedl .
The actuarial risk of sudden death for all nonresponders was
8 - 3% at 2 years and 155 '- 61 at 5 years (Fig . 4)
.
Role of implantable defibrlllatar . Selection bias was ap-
plied in determining whether a neenresponder received an
implantable defibrillator because this decision was often
based an a subjective clinical impression regarding a pa-
tien s overall prognosis . Accordingly, patients who did not
receive the defibrillator were significantly more likely to
experience nonsudden death during follow-up (21 such
deaths in 38 patients) than were patients who received a
rrem
anhylheic events
eEF
C
30 versus EF > 30, p e 0A I: vEF s 30 versus EF > 30,p<0
.001 .
EF = left ventricular ejection fraction .
217 palings
aecunen7 Arrhythmia
Events
Sudden Death Overall Dealt
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'Rupunlon of patients without inducible v+,nrri-uta : tachycantia, p <
0 .001 . comparing patients with versus those without coronary artery disease .
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Influence of the presence of coronary artery disease on
recurrent arrhythmic events (Table
5).
Patients without cor-
onary artery disease were significantly less likely to have
inducible ventricular tachycardia during baseline testing
than were patients with coronary disease (p < 0 .001) .
However, once patients were classified by electrophysio-
logic testing, the actuarial ineidence off rec=ent arrhythmic
events was similar for patients with and without underlying
coronary artery disease for all three sub troops .
Influence of the induced baseline arrhythmia on recurrent
arrhythmic events
. Table 6 shows the outcome
of
patients
whose baseline study induced arrhythmia other *.ban sus-
tained monomorphic ventricular tachycardia . Although a
response to serial drug testing tended to predict a more
favorable outcome even in these patients . that tendency did
not reach significance (probably because of the small number
of patients in this subgroup) .
Table 6 . Influence of Baseline Arrhythmia on Outcome in 136 Patients
Years Follow-up
4011
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Figure 5 . Actuarial outcome for 70 recipients of the implantable
defibrillator. The table beneath the figure gives the number of
patients (numeratost and the percent standard error (denominator)
for each actuarial curve at yearly intervals of follow-up
. Abbrevia-
tions as in Figure I .
Influence of the implantable defibrilillator on survival- Sev-
eiaty 325/) of the 217 survivors of cardiac arrest received an
implantable defibrillator as primary therapy for prevention of
sudden death . Only 2 of the 30 patients with an implantable
defibrillator who had recurrent arrhythmic events died sud-
denly (7%) compared with 23 (77%) of 30 patients without a
defibrillator who had recurrent arrhythmic events (p <
0 .001) .
The actuarial incidence rate of sudden death in recipients
clan implantable defibrillator was I ± 1% at 2 years and 3 ±
2% at 5 years (Fig. 5). The overall actuarial mortality rate for
recipients of a defibrillator was 6 ± 3% at 2 years and 21 s
'Proportion of patients responding to serial drug testing
. polymorphic ventricular tachycardia or fibrillation
versus sustained moromorphic ventricular tachycardia . p < 0.05 . NSVT = nonsustained ventricular tachycardia ;
VT = ventricular tachycardia
: VTiV F = polymorphic ventricular tachycardia or fibrillation .
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Inducible VT
Sustained, monomorphic
15-77, a-717 <0.05
Polymorphic VT/PT 13 n VA 2 5 ± 5390 NS
N.-stained 0 14 0 9% N5
Palymorphic and/or nonsustained 10±7% 20!9% NS
No.
with
CAD
42
39
72
% '50
No, without CAD' 39 13 13
a
2-yr ucmorial risk of 30
at
arrhythmic
events
rn
1 .
Patients with CAD 19 5 6A 12 a 501 35 ! 65/
NO,- without
19 x 17,
is
-
1190
32
-
1391
CAD
IACC VOL 19, No. 4
FOGOROS ET AL
. 785
March 15, 1992:790-a FLECTROPHYSIOLINAC TESTING ACrER CARDIAC ARREST
Table 5. Influence of the Presence of Coronary Anery Di.cane on
tan
-
Recurrent Arrhythmic Events
so
sudden deed,
P'alirri Soup
m n aeA
m
Arrhythmia
Drag
Notlnducible Responders Nonrespanderc
araymnae - .-..
786
FOGOROS ET AL .
ELECTROPHVSIOLOGIC TESTING AFTER CARDIAC ARREST
7% at 5 years (no Patient died within 341 days of inmplants
.
Lion), The actuarial incidence of recurrent arrhythmic events
in defibrillator recipients was 40 ± 6% at 2 years and 50 ±
7% at 5 years . Assuming that these recurrent arrhythmic
events would have resulted in sudden death had the defibril-
tutor not been implanted, the yresumed sudden death mor-
tality vithnut the implantable defibrillator -old have he-
significantly higher than both the measured sudden death
mortality (p < 0 .001) and the measured overall mortality if,
< 0.011 in defibrillator recipients
.
Discussion
This report applies actuarial methods to esandne the
long-term outcome of survivors or cardiac arrest whuse
therapy was guided by electrophysioiogic testior ;. It confirms
and extends several previous observations . Our results
regarding the proportion of cardiac arrest survivors who
have inducible arrhythmia and who respond to drug testing
are quite typical (1,2,4-7) . Our series also confirms previous
reports (2,4 .7)
that the electraphysiologic study is useful in
subgrouping survivors of cardiac arrest into categories of
patients who have a relatively high risk (nonresponders) and
a relatively low risk (patients without inducible arrhythmias
and drug responders) of recurrent arrhythmic events .
NonrTsponders. A major challenge to electrophysiolo-
gists caring for survivors of cardiac arrest has been to reduce
the risk of sudden death in the high risk subgroup (the
nonresponders) . In the present study the selective use of an
implantable defibrillator reduced the sudden death mortality
in nonresponders to the extent that their actuarial incidence
rates of sudden death and overall mortality were virtually
identical with those of the two lower risk groups (Fig. 3 and
4) despite a significantly higher incidence of recurrent ar-
rhythmic events .
Onrdecisian I^ [rear
es -v-pander nigh
as brrplarrveble
defibrillator was partly bused on a subjective assessment of
whether the patient was likely to survive surgery and remain
alive for an extended period after implantation . Our results
suggest that the decision to withhold the implantahle defibril-
lator in some nonresponders was reasonable. Although 8 of
the 311
non-ponders
who did not receive an imnlamahle
defibrillator died suddenly, "I (70%) of the remaining 30
experienced nonsudden death
. Because none of our patients
who received an implantable defibrillator died in the pcrio-
perative period, it is not at all clear that the more aggressive
use of the implantable defibrillator in our "sicker nonre-
sponders would 'Tave further reduced overall mortality .
Prospective studies are indicated to develop criteria for
deciding which high risk patients are most likely to benefit
from defibrillator implantation .
Patients withoul inducible arrhythmias . Although many
early reports (7-9) suggested that survivors of cardiac arrest
who had no inducible arrhythmia had an excellent prognosis,
later reports (1 2,41 tended to suggest a less benign progno-
sis . The present data are in agreement with these later
1 ACC V .I. 19. Na . 4
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reports. Although our patients with no inducible arrhythmia
had significantly fewer recurrent arrhythmic events than did
our nonresponders, they nonetheless had a cumulative inci-
dence of recurrent events and also a cumulative incidence of
sudden death (in thusu who did not receive an implantable
defibrillator) of approximately 6%!year .
Our patients without inducible arrhythmia in whom a
possible reversible cause for the initial cardiac arrest could
be idenhfed, fared no better as a group than the patients in
whom a reversible cause was not found. However, consis-
tent with the findings of others only I of the 20
patients in whom cardiac ischemia was believed to be the
cause of the presenting arrhythmia had a recurrent event
after the ischemia was adequately treated . As in the study of
Wilber el al . (21, nor patients who had no inducible arrhyth-
mia had a lower incidence of underlying cardiac disease than
did patients with inducible arrhythmia, and patients without
inducible arrhytania who had a higher ejection fraction had
significantly fewer arrhythmic events than did those with a
lower ejection fraction.
Many elcctrophysiologists now consider the implantable
defibrillator to be indicated for survivors of cardiac arrest
who have no inducible arrhythmia during baseline testing
1131. and the Health Care Financing Administration no
longer requires arrhythmia inducibility as a requirement for
the implantable defibrillator under Medicare (14). Our data,
which estimate a 5-year risk of sudden death approaching
30°x% in survivors of cardiac arrest who have no inducible
arrhythmia and are not treated with an implantable defibril-
lator, support the use of this device in such patients
.
However. not all such patients may benefit . Patients whose
in'''tial arrhythmia was precipitated by cardiac ischemia prob-
ably do not peed the device. Patients with a higher ejection
fraction might appear to be less likely candidates than those
with a lower ejection fraction
: however, these may he the
very patients who would receive the greatest long-term
benefit from the device-a nearly 20% 5-year incidence rate
of recurrent arrhythmic events may not be acceptable in
patients with an otherwise high likelihood of surviving for
many years . A prospective, randomized study would be
helpful in evaluating the optimal use of the implantable
dethrillamr in survivors of cardiac arrest who do not have
inducible arrhythmia .
Drug responders. Since the earliest reports (15,16) de-
scribing the efficacy, of serial drug testing in patients with
inducible ventricular tachycardia . very little has been writ-
ten about the long-term prognosis of drug responders . The
actuarial incidence of recurrent arrhythmic events in our
drug responders (approximately 5%lyear) was significantly
lower than for nonresponders, was quite similar to that seen
in patients who had no inducible arrhythmia during baseline
testing and was consistent with the few previous studies
(2.15) reporting actuarial data for drug responders . Drug
responders in our series tended to have a higher ejection
fraction than that of nonresponders and drug responders
with an ejection fraction >30% tended to have fewer recur-
JACC Vol. 19 . No. 4
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rent arrhythmias than did those with a lower ejection frac-
tion .
Whether the prognosis of drug responders would he
improved by the implantahle defibrillator has seldom been
addressed in published studies,
even though these patients
have an outcome similar to that of patients without inducible
arrhythmia (who frequently are treated with the device) .
Because we did not implant the defibrillator in drug respond-
ers, our darn do not shed light on this issue . However . if the
device is provided to patients without inducible arrhythmia .
its use in drug responders at least deserves to be studied .
Once again, a prospective
. randomized study is called for.
Limitations
. The major limitation of this study is that it is
a retrospective analysis . Thus, to a large extent the data
cannot he used to make firm recommendations regarding
therapy for survivors of cardiac arrest but instead should be
used to add confirmatory evidence to previous retrospective
reports and to suggest trends that can he subjected To
prospective study .
Because many of the patients in this study received the
implantable defibrillator . esitnlating the incidence of recur-
rent arrhythmic events required making an assessment of
whether shocks delivered by the device were appropriate . It
is well recognized that making this assessment is prnhle-
matic . We have discussed this issue in detail 117) and have
presented evidence that our definition of appropriate shocks
may err on the side of underestimating the true incidence of
arrhythmia recurrence . If so, our analysis would tend to
underestimate the benefit conferred by the implantable de-
fibrillator . Any report attempting to tabulate recurrent ar-
rhythmic events in patients with the implantahle defibrillator
will be subject to the same limitation until these devices are
capable of storing relevant electrograms .
We did not routinely use beta-blocking medication in
patients who survived cardiac arrest and are not able to
estimate any effect that the occasional prescription of these
drugs by our referring physicians might have had on patient
outcome .
The appropriate Categorization of survivors of cardiac
arrest in whom no sustained ntonomorphic tuclt_vcurdia is
reduced during baseline testing is difficult . However. in
using the electrophysiologic study to manage these patients
one must determine whether to use sulyptimal baseline
arrhythmias as markers for serial drug teeing
. Our decision
to consider nonsustained and polymorphit tachycardias as
appropriate markers for therapy was based oil 1) the Bayes
theorem, which suggests that a "positive" study is relatively
likely to be truly positive in patients who have had a
spontaneous cardiac arrest ; and 2) the fact that without use
of these markers, there were almost no other logaal ap-
proaches to therapy because the implantable defibrillator
was generally not considered acceplab! •s therapy For patients
without inducible arrhythmias du ing most of our study . Our
results showed that serial drug testing aimed at these sub-
optimal arrhythmias tended to be useful, but the number of
patients treated was too small to show statistical signifi-
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canoe . Thus. although the data tend to validate our ap-
proach . they do not do so definitively . Now that the imp(anl-
able defibrillator is generally accepted as therapy for
survivors of cardiac arrest with noninducibte arrhythmia, a
prospective study (with defibrillator backup) of the predic-
tive value of serial drug resting in such patients is feasible-
Conclusions. In 217 survivors of cardiac arrest etectro-
physiologic testing was helpful in directing therapy by sub-
grouping patients into high and low risk prognostic catego-
ries . Patients who left the electrophysinlogy laboratory
without inducible arrhythmia tatter either baseline or suc-
cessful serial drug testing) had a significantly lower actuarial
risk of recurrent arrhythmic events titan did patients whose
arrhythmia remained inducible
. Selective use
of the implant-
able defibrillator significantly reduced
sudden death mortal-
ity and overall mortality in high risk patients (ronre-
sponders) and also seemed to reduce the risk of sudden
death in patients with noninducibte arrhythmia . Prospective
studies are indicated 1) to optimize the decision of which
nonrcsponders and which patients witls roninducibte ar-
rhythntta should receive the implantable defibrillator, and
2) to assess the potential benefit of the implantable defibril-
lator in survivors of cardiac arrest who respond to drugs
during serial electrophysiologic
testing.
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